Symbols

GLPG

Galapagos·NASDAQ

--(--)

GLPG fundamentals

GLPG Q4 2025 Earnings

Galapagos (GLPG) released its earnings on Feb 23, 2026: revenue was 83.33M (YoY +5.07%), beat estimates; EPS was -0.162 (YoY -153.59%), missed estimates.

Revenue / YoY

83.33M

+5.07%

EPS / YoY

-0.162

-153.59%

Report date

Feb 23, 2026

GLPG Earnings Call Summary for Q4,2025

Strategic Shift Confirmed: Transitioned from cell therapy to late-stage assets, with EUR 3 billion in cash for selective deals.
GLPG3667 Update: Phase II success in dermatomyositis/SLE; evaluating partnerships for Phase III to minimize capital risk.
Cost Efficiency: 2026 restructuring costs reduced to EUR 125-175 million (down from EUR 150-200 million), with cash flow neutrality expected by year-end.
Gilead Synergy: Potential for Gilead to co-fund deals, expanding Galapagos' deal capacity beyond its cash reserves.

Earnings

EPS

Revenue

Revenue & Expenses

GLPG has released its 2025 Q4 earnings report, with revenue of 1.06B, reflecting a YoY change of 1252.88%, and net profit of 917.93M, showing a YoY change of 3404.17%. The Sankey diagram below clearly presents GLPG's revenue sources and cost distribution.

Key Indicators

Galapagos (GLPG) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Galapagos (GLPG)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Galapagos (GLPG)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Galapagos (GLPG)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown